Articles publicats

Articles publicats 1 registres trobats  La cerca s'ha fet en 0.00 segons. 
1.
15 p, 598.6 KB Five Year Survival Update From KEYNOTE-010 : Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC / Herbst, Roy S (Section of Medical Oncology. Yale Comprehensive Cancer Center. Yale University School of Medicine) ; Garon, E.B. (David Geffen School of Medicine. University of California Los Angeles) ; Kim, D.W. (Seoul National University Hospital. Seoul National University College of Medicine) ; Cho, B.C. (Yonsei Cancer Center. Yonsei University College of Medicine) ; Gervais, R. (Centre François Baclesse (Caen, França)) ; Perez-Gracia, J.L. (Clínica Universidad de Navarra) ; Han, J.Y. (Center for Lung Cancer. National Cancer Center) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Forster, M.D. (UCL Cancer Institute/University College London Hospitals) ; Monnet, Isabelle (Centre Hospitalier Intercommunal de Créteil) ; Novello, Silvia (Department of Oncology. University of Turin. Azienda Ospedaliero Universitaria San Luigi) ; Gubens, M.A. (University of California. San Francisco) ; Boyer, M. (Chris O'Brien Lifehouse) ; Su, W.C. (National Cheng Kung University Hospital) ; Samkari, A. (Merck & Co.. Inc.) ; Jensen, E.H. (Merck & Co.. Inc.) ; Kobie, J. (Merck & Co.. Inc.) ; Piperdi, B. (Merck & Co.. Inc.) ; Baas, Pieter (The Netherlands Cancer Institute (Amsterdam, Països Baixos))
Introduction: In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in patients with previously treated, advanced NSCLC with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) ≥50% and ≥1%. [...]
2021 - 10.1016/j.jtho.2021.05.001
Journal of Thoracic Oncology, Vol. 16 Núm. 10 (october 2021) , p. 1718-1732  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.